Galectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder James C. Czirr Sells 21,323 Shares of Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) major shareholder James C. Czirr sold 21,323 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $3.06, for a total transaction of $65,248.38. Following the completion of the transaction, the insider now owns 5,925,884 shares of the company’s stock, valued at approximately $18,133,205.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Galectin Therapeutics Price Performance

GALT stock opened at $3.50 on Friday. The firm has a 50-day simple moving average of $2.54 and a 200-day simple moving average of $2.10. Galectin Therapeutics Inc. has a 52 week low of $1.28 and a 52 week high of $4.27.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Friday, March 29th. The company reported ($0.16) EPS for the quarter. On average, analysts predict that Galectin Therapeutics Inc. will post -0.66 EPS for the current fiscal year.

Institutional Trading of Galectin Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. AE Wealth Management LLC grew its stake in Galectin Therapeutics by 72.7% during the 3rd quarter. AE Wealth Management LLC now owns 26,841 shares of the company’s stock valued at $52,000 after acquiring an additional 11,300 shares in the last quarter. D.A. Davidson & CO. grew its stake in Galectin Therapeutics by 15.2% during the 3rd quarter. D.A. Davidson & CO. now owns 37,825 shares of the company’s stock valued at $73,000 after acquiring an additional 5,000 shares in the last quarter. Beacon Capital Management LLC grew its stake in Galectin Therapeutics by 89.6% during the 4th quarter. Beacon Capital Management LLC now owns 23,905 shares of the company’s stock valued at $40,000 after acquiring an additional 11,300 shares in the last quarter. Retirement Guys Formula LLC grew its stake in Galectin Therapeutics by 87.0% during the 4th quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company’s stock valued at $36,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Solutions 4 Wealth Ltd purchased a new stake in Galectin Therapeutics during the 4th quarter valued at about $60,000. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. StockNews.com upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, April 9th.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.